



## In the News

To cite this article: (1998) In the News, Oncology Issues, 13:4, 16-16, DOI: [10.1080/10463356.1998.11904761](https://doi.org/10.1080/10463356.1998.11904761)

To link to this article: <https://doi.org/10.1080/10463356.1998.11904761>



Published online: 18 Oct 2017.



Submit your article to this journal [↗](#)



Article views: 1



View related articles [↗](#)

## A HEARTY WELCOME TO ACCC'S NEWEST MEMBERS!

- Cape Fear Valley Health System, Fayetteville, N.C.
- Henry Ford Health System, Detroit, Mich.
- M.D. Anderson Cancer Network - Tarrant County, Fort Worth, Tex.
- Mission Hospital Regional Medical Center, Mission Viejo, Calif.
- Our Lady of Bellefonte Hospital, Ashland, Ky.
- University of Pittsburgh Cancer Institute, Pittsburgh, Pa.
- Wausau Hospital Regional Cancer Center, Wausau, Wisc.



Remember when  
all the answers  
were in one place?

- Search free full-text articles & MEDLINE
- Read *Oncology Issues* online
- Order free drug samples
- Earn CME credits
- Get free, easy-to-use email

**Medscape** The #1  
Free Internet  
Medical Site  
[www.medscape.com](http://www.medscape.com)

A9801 ©1997 Medscape, Inc.

## IN THE NEWS

### NSABP ANNOUNCES THE STAR BREAST CANCER PREVENTION TRIAL

The National Surgical Adjuvant Breast and Bowel Project (NSABP) is inviting institutions to submit applications to participate in a new breast cancer prevention trial, a *Study of Tamoxifen and Raloxifene (STAR)*. STAR is a large-scale, chemoprevention clinical trial that will compare the efficacy of five years of tamoxifen therapy to five years of raloxifene therapy in preventing invasive breast cancer among study participants. Up to 22,000 postmenopausal women over the age of 35 will ultimately be enrolled in this double-blind, randomized clinical trial. Approximately 200 clinical centers in North America will participate in the trial, which is expected to begin this fall. All applications will be peer-reviewed, with final approval of clinical centers made by the NSABP Membership Committee. STAR is supported by the National Cancer Institute, Eli Lilly and Company, and Zeneca Pharmaceuticals.

To request an application form or additional information, mail a letter of interest to: Gladys Hurst, Assistant Director, Membership Affairs Section, NSABP Operations Center, East Commons Professional Building, Four Allegheny Center-5<sup>th</sup> Floor, Pittsburgh PA 15212-5234, or fax the information to her attention at 412-330-4662. Applications must be returned to the NSABP by August 15, 1998.

### A LIFELINE IN THE SKIES

AirLifeLine is a national nonprofit organization of private pilots who transport ambulatory patients in need of life-sustaining treatments to medical facilities far from home, at no charge to the patient or referring agency. AirLifeLine services are available for people of all ages and any diagnosed illness. Transportation is also provided for an accompanying parent or other family member wishing to travel with the patient.

AirLifeLine pilots donate their time, aircraft, fuel, and all expenses to transport passengers to treatment. Pilots can be available day or night to transport patients, as well as human organs needing transportation, and time-critical medical cargo.

AirLifeLine, based in Sacramento, Calif., offers its services to all qualified patients within the United States, including Alaska. To qualify, patients must be ambulatory and demonstrate financial need. Distance limitations may apply. For more information about AirLifeLine and its services, call 1-800-446-1231, or visit its web site at [www.airlifeline.org](http://www.airlifeline.org).

The Corporate Angel Network, Inc., in White Plains, N.Y., provides a similar service. For more information, call 914-328-1313 or e-mail [corpangl@ix.net-com.com](mailto:corpangl@ix.net-com.com).